MS Treatments

The below disease modifying treatments (DMT’s) are available for the treatment of MS in New Zealand.

First line treatments for Relapsing Remitting MS (funded)

Gilenya® (Fingolimod)

Aubagio® (teriflunomide)

Tecfidera® (Dimethyl fumarate)

Tysabri® (Natalizumab)

Second line treatments for Relapsing Remitting MS (funded)

Copaxone® (glatiramer acetate)

Interferons

Disease Modifying Treatment Special Authority Criteria

Information on the entry and exit criteria for the PHARMAC funded treatments and application process.

Disease modifying treatments (DMTs) not currently funded in NZ but under consultation

Ocrevus® (Ocrelizumab)

Other disease modifying treatments (DMTs) and symptom management medications (available in NZ but not-funded)

Mavenclad® (Cladribine)

Sativex® (Nabiximols)

Fampyra® (fampridine)

LDN-Low-Dose Naltrexone (LDN)

Steroids

Disease modifying treatments (DMTs) not currently available in NZ

Stem Cell Treatment